Gullion G, Yeh H S
Napa State Hospital, Calif.
J Clin Psychiatry. 1994 Sep;55(9):401-5.
Is clozapine-induced agranulocytosis amenable to treatment with recombinant granulocyte colony-stimulating factor (rG-CSF)? Will this treatment provide benefits in terms of morbidity, mortality, and costs compared with current treatment?
Five patients with clozapine-induced agranulocytosis (granulocytes < 500/cu mm) were treated with the rG-CSF filgrastim, in addition to standard agranulocytosis therapy protocol.
Time from onset until resolution of agranulocytosis was 8.2 +/- 2.1 days compared with a historical study of seven cases where filgrastim was not used and 15.7 +/- 3.7 days were required for resolution.
rG-CSF (filgrastim) may be an effective and cost-reducing way to provide improved treatment for clozapine-induced agranulocytosis. More research is required.
氯氮平所致粒细胞缺乏症是否可用重组粒细胞集落刺激因子（rG-CSF）治疗？与当前治疗相比，这种治疗在发病率、死亡率和成本方面是否具有优势？
除标准粒细胞缺乏症治疗方案外，对5例氯氮平所致粒细胞缺乏症（粒细胞＜500/立方毫米）患者使用rG-CSF非格司亭进行治疗。
粒细胞缺乏症从发病到缓解的时间为8.2±2.1天，而在一项未使用非格司亭的7例病例的历史研究中，缓解需要15.7±3.7天。
rG-CSF（非格司亭）可能是一种有效且能降低成本的方法，可为氯氮平所致粒细胞缺乏症提供更好的治疗。还需要更多研究。
